The group's principle activity is to provide curative therapies for seriously ill patients. The group develops a novel, cell-based medicine (Myeloid Progenitors / CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for acute radiation syndrome. The group operates from United States.
